Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis.
Marieta P TheodorakopoulouMaria-Eleni AlexandrouAlexandros TsitouridisVasileios KamperidisEva PellaAndrew XanthopoulosAntonios ZiakasFilippos TriposkiadisVassilios VassilikosAikaterini PapagianniPantelis A SarafidisPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
Treatment with SGLT-2 inhibitors led to a significant reduction in HF events in patients with CKD. Such findings may change the landscape of prevention of HF events in patients with advanced CKD. PROSPERO Registration number CRD42022382857.